Macrophage Migration Inhibitory Factor (MIF) Plasma Concentration in Critically Ill COVID-19 Patients: A Prospective Observational Study.

摘要: Mortality in critically ill coronavirus disease 2019 (COVID-19) patients is high and pharmacological treatment strategies remain limited. Early-stage predictive biomarkers are needed to identify with a risk of severe clinical courses stratify strategies. Macrophage migration inhibitory factor (MIF) was previously described as potential predictor for the outcome acute respiratory distress syndrome (ARDS), hallmark COVID-19 disease. This prospective observational study evaluates MIF after infection. Plasma concentrations were measured 36 mechanically ventilated over three days intensive care unit (ICU) admission. Increased compared decreased significantly associated aggravated organ function lower 28-day survival (sequential failure assessment (SOFA) score; 8.2 ± 4.5 14.3 3, p = 0.009 vs. 8.9 1.9 12 2, 0.296; survival: 56% 93%; 0.003). Arterial hypertension predominant comorbidity 85% increasing (vs. decreasing MIF: 39%; 0.015). Without reaching significance, more able improve their ARDS status (p 0.142). The identified association between an early response, aggravation may open future perspectives biomarker-based diagnostic approaches ICU management patients.